p.5 抽出テキスト

............................................................................................................................................................................ Evacetrapib in Patients at a High-Risk for Vascular Outcomes ACCORD Action to Control Cardiovascular Risk in Diabetes ACS Acute coronary syndrome ALT Alanine aminotransferase ANGPTL3 Angiopoietin-like protein 3 Apo Apolipoprotein ART Antiretroviral treatment ASCEND A Study of Cardiovascular Events iN Diabetes ASCOT-LLA Anglo-Scandinavian Cardiac Outcomes Trial  Lipid-Lowering Arm ASCVD Atherosclerotic cardiovascular disease ASSIGN CV risk estimation model from the Scottish Intercollegiate Guidelines Network AURORA A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events b.i.d. Twice a day (bis in die) BIOSTAT-CHF BIOlogy Study to TAilored Treatment in Chronic Heart Failure BIP Bezafibrate Infarction Prevention BMI Body mass index BP Blood pressure CABG Coronary artery bypass graft surgery CAC Coronary artery calcium CAD Coronary artery disease CANTOS Canakinumab Antiinflammatory Thrombosis Outcome Study CETP Cholesteryl ester transfer protein CHD Coronary heart disease CI Confidence interval CIID Chronic immune-mediated inflammatory diseases CIRT Cardiovascular Inflammation Reduction Trial CK Creatine kinase CKD Chronic kidney disease COM-B Capability, Opportunity and Motivation CORONA Controlled Rosuvastatin Multinational Trial in Heart Failure CPG Committee for Practice Guidelines CT Computed tomography CTT Cholesterol Treatment Trialists CV Cardiovascular CVD Cardiovascular disease CYP Cytochrome P450 4D Die Deutsche Diabetes Dialyse Studie dal-OUTCOMES Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome DASH Dietary Approaches to Stop Hypertension DGAT-2 Diacylglycerol acyltransferase-2 DHA Docosahexaenoic acid DM Diabetes mellitus EAPC European Association of Preventive Cardiology EAS European Atherosclerosis Society EBBINGHAUS Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects eGFR Estimated glomerular filtration rate EMA European Medicines Agency EPA Eicosapentaenoic acid ESC European Society of Cardiology EVOLVE EpanoVa fOr Lowering Very high triglyceridEs EVOPACS EVOlocumab for early reduction of LDLcholesterol levels in patients with Acute Coronary Syndromes FCH Familial combined hyperlipidaemia FCS Familial chylomicronaemia syndrome FDA US Food and Drug Administration FH Familial hypercholesterolaemia FIELD Fenofibrate Intervention and Event Lowering in Diabetes FOCUS Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention FOURIER Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk GFR Glomerular filtration rate GI Gastrointestinal GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico HbA1c Glycated haemoglobin HeFH Heterozygous familial hypercholesterolaemia HDL High-density lipoprotein HDL-C High-density lipoprotein cholesterol HF Heart failure HHS Helsinki Heart Study HIV Human immunodeficiency virus HMG-CoA Hydroxymethylglutaryl-coenzyme A HoFH Homozygous familial hypercholesterolaemia HPS2-THRIVE Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events HR Hazard ratio HTG Hypertriglyceridaemia IDEAL Incremental Decrease In End-points Through Aggressive Lipid-lowering IDL Intermediate-density lipoproteins IL Interleukin ILLUMINATE Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efficacy International Trial IPD Individual participant data JUPITER Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin KDIGO Kidney Disease: Improving Global Outcomes LCAT Lecithin cholesterol acyltransferase LDL Low-density lipoprotein LDL-C Low-density lipoprotein cholesterol LDLR Low-density lipoprotein receptor LEAD Lower extremity arterial disease Downloaded from academic.oup.com/eurheartj/article/41/1/111/5556353 by guest on 07 October 2026